The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
Open accessAbstract
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH. METHODS: Eleven transfusion-dependent patients with PNH received infusions of eculizumab (600 mg) every week for four weeks, followed one week later by a 900-mg dose and then by 900 mg every other week through week 12. Clinical and biochemical indicators of hemolysis were measured throughout the trial. RESULTS: Mean lactate dehydrogenase levels decreased from 3111 IU per liter before treatment to 594 IU per liter during treatment (P=0.002). The mean percentage of PNH type III erythrocytes increased from 36.7 percent of the total erythrocyte population to 59.2 percent (P=0.005). The mean and median transfusion rates decreased from 2.1 and 1.8 units per patient per month to 0.6 and 0.0 units per patient per month, respectively (P=0.003 for the comparison of the median rates). Episodes of hemoglobinuria were reduced by 96 percent (P<0.001), and measurements of the quality of life improved significantly. CONCLUSIONS: Eculizumab is safe and well tolerated in patients with PNH. This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Natural History of Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L., & Dacie, J. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331904 · Cited by 907
Self-citationRollins, S. A., & Sims, P. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3478 · Cited by 405
Self-citationHolguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A., & Parker, C. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114172 · Cited by 403
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
Bessler, M., Mason, P. J., Hillmen, P., Miyata, T., Yamada, N., Takeda, J., Luzzatto, L., & Kinoshita, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06240.x · Cited by 389
Self-citationInhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Self-citationA clinical safety trial of stroma‐free hemoglobin
Savitsky, J. P., Doczi, J., Black, J., & Arnold, J. D. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197823173 · Cited by 359
Yamashina, M., Ueda, E., Kinoshita, T., Takami, T., Ojima, A., Ono, H., Tanaka, H., Kondo, N., Orii, T., Okada, N., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010253231707 · Cited by 351
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationThe Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Self-citationDiagnosis and management of paroxysmal nocturnal hemoglobinuria
Parker, C. (2005) · Blood · doi:10.1182/blood-2005-04-1717 · Cited by 783
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Brodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.-L., et al. (2008) · Blood · doi:10.1182/blood-2007-06-094136 · Cited by 652
Self-citationNoris, M., & Remuzzi, G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100861 · Cited by 635
Hillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Self-citationGuidelines for the diagnosis and management of aplastic anaemia
Marsh, J. C. W., Ball, S. E., Cavenagh, J., Darbyshire, P., Dokal, I., Gordon‐Smith, E. C., Keidan, J., Laurie, A., Martin, A., Mercieca, J., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07842.x · Cited by 560
Self-citationKelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Self-citationThrombosis in paroxysmal nocturnal hemoglobinuria
Hill, A., Kelly, R. J., & Hillmen, P. (2013) · Blood · doi:10.1182/blood-2012-09-311381 · Cited by 478
Self-citationParoxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Genetic Variants in C5 and Poor Response to Eculizumab
Nishimura, J.-I., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A. L., Noji, H., Kitamura, K., Eto, T., Takahashi, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311084 · Cited by 417
Borowitz, M. J., Craig, F. E., DiGiuseppe, J. A., Illingworth, A. J., Rosse, W., Sutherland, D. R., Wittwer, C. T., & Richards, S. J. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20525 · Cited by 403
Self-citationPittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
Hillmen, P., Muus, P., Röth, A., Elebute, M. O., Risitano, A. M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J. P., Schubert, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12347 · Cited by 394
Self-citationParoxysmal nocturnal hemoglobinuria: natural history of disease subcategories
de Latour, R. P., Mary, J. Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de Guibert, S., Maury, S., Cahn, J. Y., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133918 · Cited by 378
Pierangeli, S. S., Girardi, G., Vega‐Ostertag, M., Liu, X., Espinola, R. G., & Salmon, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21157 · Cited by 362
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., et al. (2009) · Blood · doi:10.1182/blood-2008-11-189944 · Cited by 361
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808527 · Cited by 346
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Inhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Kelly, R. J., Höchsmann, B., Szer, J., Kulasekararaj, A., de Guibert, S., Röth, A., Weitz, I. C., Armstrong, E., Risitano, A. M., Patriquin, C. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502950 · Cited by 286
Parallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280
“A trial using systemic administration of eculizumab, a humanised anti-C5 antibody used for the treatment of paroxysmal nocturnal haemoglobinuria (Hillmen et al., 2004), has been approved by the FDA to examine its use in geographic atrophy.”
BackgroundGoonewardene, M., Shehata, M., & Hamad, A. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.010 · Cited by 277
Schrezenmeier, H., Muus, P., Socie, G., Szer, J., Urbano-Ispizua, A., Maciejewski, J. P., Brodsky, R. A., Bessler, M., Kanakura, Y., Rosse, W., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.093161 · Cited by 270
Self-citationNishimura, J.-I., Kanakura, Y., Ware, R. E., Shichishima, T., Nakakuma, H., Ninomiya, H., Decastro, C. M., Hall, S., Kanamaru, A., Sullivan, K. M., et al. (2004) · Medicine · doi:10.1097/01.md.0000126763.68170.46 · Cited by 261
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans
Hillebrandt, S., Wasmuth, H. E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R., Wilkens, G., Geier, A., Lorenzen, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1599 · Cited by 258
Role of the Red Blood Cell in Nitric Oxide Homeostasis and Hypoxic Vasodilation
Gladwin, M. T. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-34817-9_17 · Cited by 59
Amer, J., Zelig, O., & Fibach, E. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.12.003 · Cited by 44
Metadata
- Authors
- Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., & Rother, R. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-02-05
- Volume
- 350
- Issue
- 6
- Pages
- 552-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152757679
- Cited by
- 635
- References
- 22
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.